Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > U.S. funding 1.6B$ for Novavax's COVID-19

<< Previous

Bullboard Posts

Next >>

Post by ScienceFirston Apr 19, 2022 2:50pm

186 Views

Post# 34614085

U.S. funding 1.6B$ for Novavax's COVID-19

Examples of canadian-made Novavax vaccine that shines worldwide and that could happen to TLT, if it answers a specific unmet need:

U.S. funding to now cover study of Novavax's COVID-19 shot in adolescents

Feb 7, 2022 (Reuters) - Novavax Inc (NVAX.O) said on Monday U.S. government funding for its COVID-19 vaccine had been expanded to cover a late-stage study in adolescents with a booster component.

Novavax in July 2020 had received $1.6 billion in funding to develop its protein-based vaccine under a government program aimed at accelerating access to coronavirus vaccines and treatments, formerly called Operation Warp Speed.

Swissmedic grants conditional marketing authorization for Novavax COVID-19 vaccine for individuals aged 18 years or older in Switzerland.

Feb. 13, 2022 - Singapore grants interim approval for Novavax's COVID-19 ...

April 14, 2022 - Thai FDA grants EUA to Novavax-Serum Institute's Covid-19 ...